10-Q Filing

CARGO THERAPEUTICS, INC. CIK: 1966494 Q2 2024

Filing Information

Form Type	10-Q
Accession Number	`0000950170-24-095427`
Period End Date	20240630
Filing Date	20240812
Fiscal Year	2024
Fiscal Period	Q2
XBRL Instance	crgx-20240630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 96 Income Statement 112 Cash Flow Statement 162 Stockholders Equity 78

Balance Sheet 96 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$42.37M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$42.37M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$405.73M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$405.73M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$153.58M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$153.58M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$289.90M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$289.90M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$3.75M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$3.75M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$4.62M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$4.62M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$409.48M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$409.48M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$448.10M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$448.10M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$25.14M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$25.14M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$28.22M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$28.22M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$10.38M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$10.38M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$11.84M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$11.84M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$4.39M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$4.39M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$4.38M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$4.38M	USD	Point-in-time
Total assets	`Assets`	$453.04M	USD	Point-in-time
Total assets	`Assets`	$453.04M	USD	Point-in-time
Total assets	`Assets`	$490.01M	USD	Point-in-time
Total assets	`Assets`	$490.01M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$5.01M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$5.01M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$7.01M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$7.01M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$7.24M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$7.24M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$13.13M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$13.13M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$5.63M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$5.63M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$6.63M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$6.63M	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$649.00K	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$649.00K	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$2.28M	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$2.28M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$26.42M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$26.42M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$21.16M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$21.16M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$26.26M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$26.26M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$27.49M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$27.49M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$225.00K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$225.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$47.65M	USD	Point-in-time
Total liabilities	`Liabilities`	$47.65M	USD	Point-in-time
Total liabilities	`Liabilities`	$53.91M	USD	Point-in-time
Total liabilities	`Liabilities`	$53.91M	USD	Point-in-time
Common stock	`CommonStockValue`	$46.00K	USD	Point-in-time
Common stock	`CommonStockValue`	$46.00K	USD	Point-in-time
Common stock	`CommonStockValue`	$41.00K	USD	Point-in-time
Common stock	`CommonStockValue`	$41.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$550.49M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$550.49M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$661.68M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$661.68M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-323.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-323.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-145.15M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-145.15M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-225.31M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-225.31M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$405.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$405.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-74.98M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-74.98M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$373.21M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$373.21M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-57.76M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-57.76M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$436.10M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$436.10M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$490.01M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$490.01M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$453.04M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$453.04M	USD	Point-in-time

Income Statement 112 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$37.46M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$37.46M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$67.96M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$67.96M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$26.49M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$26.49M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$13.93M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$13.93M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.87M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.87M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$6.55M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$6.55M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$11.86M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$11.86M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$22.16M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$22.16M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$17.80M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$17.80M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$49.32M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$49.32M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$33.04M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$33.04M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$90.12M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$90.12M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-33.04M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-33.04M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-49.32M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-49.32M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-17.80M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-17.80M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-90.12M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-90.12M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$578.00K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$578.00K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$9.99M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$9.99M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$683.00K	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$683.00K	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$4.99M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$4.99M	USD	1 Quarter
Interest expense	`InterestExpense`	$1.60M	USD	2 Qtrs
Interest expense	`InterestExpense`	$1.60M	USD	2 Qtrs
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$692.00K	USD	2 Qtrs
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$692.00K	USD	2 Qtrs
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$634.00K	USD	1 Quarter
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$634.00K	USD	1 Quarter
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	2 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	2 Qtrs
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	2 Qtrs
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	2 Qtrs
Other expense, net	`OtherNonoperatingIncomeExpense`	$-80.00K	USD	2 Qtrs
Other expense, net	`OtherNonoperatingIncomeExpense`	$-80.00K	USD	2 Qtrs
Other expense, net	`OtherNonoperatingIncomeExpense`	$-17.00K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-17.00K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-27.00K	USD	2 Qtrs
Other expense, net	`OtherNonoperatingIncomeExpense`	$-27.00K	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-17.85M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-17.85M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-30.60M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-30.60M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.75M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.75M	USD	1 Quarter
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-323.00K	USD	2 Qtrs
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-323.00K	USD	2 Qtrs
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-44.00K	USD	1 Quarter
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-44.00K	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-17.85M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-17.85M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-80.48M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-80.48M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-44.39M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-44.39M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-30.60M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-30.60M	USD	2 Qtrs
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-26.56	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-26.56	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-1.02	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-1.02	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-48.21	USD	2 Qtrs
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-48.21	USD	2 Qtrs
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-1.90	USD	2 Qtrs
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-1.90	USD	2 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-1.90	USD	2 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-1.90	USD	2 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-1.02	USD	1 Quarter
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-1.02	USD	1 Quarter
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-26.56	USD	1 Quarter
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-26.56	USD	1 Quarter
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-48.21	USD	2 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-48.21	USD	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	42.17M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	42.17M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	634,704.00	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	634,704.00	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	672,253.00	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	672,253.00	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	43.34M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	43.34M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	634,704.00	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	634,704.00	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	43.34M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	43.34M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	672,253.00	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	672,253.00	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	42.17M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	42.17M	shares	2 Qtrs

Cash Flow Statement 162 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-17.85M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-17.85M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-30.60M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-30.60M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.75M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.75M	USD	1 Quarter
Stock-based compensation expense	`ShareBasedCompensation`	$8.21M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$8.21M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$623.00K	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$623.00K	USD	2 Qtrs
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$1.04M	USD	2 Qtrs
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$1.04M	USD	2 Qtrs
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$2.76M	USD	2 Qtrs
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$2.76M	USD	2 Qtrs
Depreciation	`Depreciation`	$600.00K	USD	1 Quarter
Depreciation	`Depreciation`	$600.00K	USD	1 Quarter
Depreciation	`Depreciation`	$499.00K	USD	2 Qtrs
Depreciation	`Depreciation`	$499.00K	USD	2 Qtrs
Depreciation	`Depreciation`	$300.00K	USD	1 Quarter
Depreciation	`Depreciation`	$300.00K	USD	1 Quarter
Depreciation	`Depreciation`	$1.17M	USD	2 Qtrs
Depreciation	`Depreciation`	$1.17M	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$150.00K	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$150.00K	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$466.00K	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$466.00K	USD	2 Qtrs
Accretion on investments in marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$3.64M	USD	2 Qtrs
Accretion on investments in marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$3.64M	USD	2 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	2 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	2 Qtrs
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	2 Qtrs
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	2 Qtrs
Noncash interest expense	`PaidInKindInterest`	$1.60M	USD	2 Qtrs
Noncash interest expense	`PaidInKindInterest`	$1.60M	USD	2 Qtrs
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$692.00K	USD	2 Qtrs
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$692.00K	USD	2 Qtrs
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$634.00K	USD	1 Quarter
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$634.00K	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$296.00K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$296.00K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$973.00K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$973.00K	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-13.00K	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-13.00K	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$3.84M	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$3.84M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.32M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.32M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$1.38M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$1.38M	USD	2 Qtrs
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$5.03M	USD	2 Qtrs
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$5.03M	USD	2 Qtrs
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$6.13M	USD	2 Qtrs
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$6.13M	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-1.13M	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-1.13M	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-523.00K	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-523.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-916.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-916.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-79.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-79.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-65.23M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-65.23M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-28.96M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-28.96M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$360.38M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$360.38M	USD	2 Qtrs
Proceeds from sales and maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$73.80M	USD	2 Qtrs
Proceeds from sales and maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$73.80M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquireProductiveAssets`	$2.75M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquireProductiveAssets`	$2.75M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquireProductiveAssets`	$2.05M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquireProductiveAssets`	$2.05M	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$830.00K	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$830.00K	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$59.00K	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$59.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-290.17M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-290.17M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.11M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.11M	USD	2 Qtrs
Proceeds from issuance of common stock in private placement, net of issuance costs	`ProceedsFromIssuanceOfPrivatePlacement`	$103.27M	USD	2 Qtrs
Proceeds from issuance of common stock in private placement, net of issuance costs	`ProceedsFromIssuanceOfPrivatePlacement`	$103.27M	USD	2 Qtrs
Proceeds from issuance of convertible notes, net of issuance costs - related party	`ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCostsFromRelatedParty`	$2.21M	USD	2 Qtrs
Proceeds from issuance of convertible notes, net of issuance costs - related party	`ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCostsFromRelatedParty`	$2.21M	USD	2 Qtrs
Proceeds from issuance of convertible notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$1.29M	USD	2 Qtrs
Proceeds from issuance of convertible notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$1.29M	USD	2 Qtrs
Proceeds from issuance of redeemable convertible preferred stock and tranche obligations, net of issuance costs	`ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndTrancheObligationsNetOfIssuanceCosts`	$68.08M	USD	2 Qtrs
Proceeds from issuance of redeemable convertible preferred stock and tranche obligations, net of issuance costs	`ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndTrancheObligationsNetOfIssuanceCosts`	$68.08M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$2.00K	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$2.00K	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$106.00K	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$106.00K	USD	2 Qtrs
Payment of deferred initial public offering costs	`PaymentsOfStockIssuanceCosts`	$105.00K	USD	2 Qtrs
Payment of deferred initial public offering costs	`PaymentsOfStockIssuanceCosts`	$105.00K	USD	2 Qtrs
Payment of transaction costs for exchange of common stock for warrants	`PaymentOfTransactionCostsForExchangeOfCommonStockForWarrants`	$25.00K	USD	2 Qtrs
Payment of transaction costs for exchange of common stock for warrants	`PaymentOfTransactionCostsForExchangeOfCommonStockForWarrants`	$25.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$103.25M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$103.25M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$71.58M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$71.58M	USD	2 Qtrs
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$40.50M	USD	2 Qtrs
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$40.50M	USD	2 Qtrs
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-252.15M	USD	2 Qtrs
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-252.15M	USD	2 Qtrs
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$42.37M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$42.37M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$42.37M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$42.37M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$154.15M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$42.37M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$42.37M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$405.73M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$405.73M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$153.58M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$153.58M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$42.37M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$42.37M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$154.15M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$154.15M	USD	Point-in-time
Exchange of common stock for pre-funded warrants	`ExchangeOfCommonStockForPrefundedWarrants`	$37.60M	USD	2 Qtrs
Exchange of common stock for pre-funded warrants	`ExchangeOfCommonStockForPrefundedWarrants`	$37.60M	USD	2 Qtrs
Conversion of convertible notes to shares of Series A-2 redeemable convertible preferred stock	`ConversionOfConvertibleNotesToSharesOfSeriesA2RedeemableConvertiblePreferredStock`	$35.58M	USD	2 Qtrs
Conversion of convertible notes to shares of Series A-2 redeemable convertible preferred stock	`ConversionOfConvertibleNotesToSharesOfSeriesA2RedeemableConvertiblePreferredStock`	$35.58M	USD	2 Qtrs
Reclassification of shares of Series Seed redeemable convertible preferred stock to mezzanine equity	`ReclassificationOfSharesOfSeriesSeedRedeemableConvertiblePreferredStockToMezzanineEquity`	$9.83M	USD	2 Qtrs
Reclassification of shares of Series Seed redeemable convertible preferred stock to mezzanine equity	`ReclassificationOfSharesOfSeriesSeedRedeemableConvertiblePreferredStockToMezzanineEquity`	$9.83M	USD	2 Qtrs
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$754.00K	USD	2 Qtrs
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$754.00K	USD	2 Qtrs
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$1.61M	USD	2 Qtrs
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$1.61M	USD	2 Qtrs
In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities`	$790.00K	USD	2 Qtrs
In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities`	$790.00K	USD	2 Qtrs
In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities`	$493.00K	USD	2 Qtrs
In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities`	$493.00K	USD	2 Qtrs
Deferred offering costs related to initial public offering included in accounts payable, accrued expenses and other current liabilities	`DeferredOfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities`	$218.00K	USD	2 Qtrs
Deferred offering costs related to initial public offering included in accounts payable, accrued expenses and other current liabilities	`DeferredOfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities`	$218.00K	USD	2 Qtrs
Deferred issuance costs for the second tranche of Series A-1 redeemable convertible preferred stock in accounts payable, accrued expenses and other current liabilities	`DeferredIssuanceCostsForSecondTrancheOfSeriesA1RedeemableConvertiblePreferredStockInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities`	$33.00K	USD	2 Qtrs
Deferred issuance costs for the second tranche of Series A-1 redeemable convertible preferred stock in accounts payable, accrued expenses and other current liabilities	`DeferredIssuanceCostsForSecondTrancheOfSeriesA1RedeemableConvertiblePreferredStockInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities`	$33.00K	USD	2 Qtrs
Deferred issuance costs related to the private placement, included in accounts payable, accrued expenses and other current liabilities	`DeferredIssuanceCostsRelatedToThePrivatePlacementIncludedInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities`	$381.00K	USD	2 Qtrs
Deferred issuance costs related to the private placement, included in accounts payable, accrued expenses and other current liabilities	`DeferredIssuanceCostsRelatedToThePrivatePlacementIncludedInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities`	$381.00K	USD	2 Qtrs

Stockholders Equity 78 line items

Line Item	Tag	Value	Unit	Period
Stock Issuance Costs	`StockIssuanceCosts`	$7.12M	USD	1 Quarter
Stock Issuance Costs	`StockIssuanceCosts`	$7.12M	USD	1 Quarter
Beginning balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Beginning balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-74.98M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-74.98M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$373.21M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$373.21M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-57.76M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-57.76M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$436.10M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$436.10M	USD	Point-in-time
Exchange of common stock for pre-funded warrants, value	`ExchangeOfCommonStockForPrefundedWarrantsValue`	$25.00K	USD	1 Quarter
Exchange of common stock for pre-funded warrants, value	`ExchangeOfCommonStockForPrefundedWarrantsValue`	$25.00K	USD	1 Quarter
Issuance of common stock in private placement, net of issuance costs, amount	`StockIssuedDuringPeriodValueNewIssues`	$102.89M	USD	1 Quarter
Issuance of common stock in private placement, net of issuance costs, amount	`StockIssuedDuringPeriodValueNewIssues`	$102.89M	USD	1 Quarter
Issuance of common stock in private placement, net of issuance costs, shares	`StockIssuedDuringPeriodSharesNewIssues`	18.75M	shares	Point-in-time
Issuance of common stock in private placement, net of issuance costs, shares	`StockIssuedDuringPeriodSharesNewIssues`	18.75M	shares	Point-in-time
Reclassification of series seed redeemable convertible preferred stock, amount	`ReclassificationOfSeriesSeedRedeemableConvertiblePreferredStockValue`	$-9.83M	USD	1 Quarter
Reclassification of series seed redeemable convertible preferred stock, amount	`ReclassificationOfSeriesSeedRedeemableConvertiblePreferredStockValue`	$-9.83M	USD	1 Quarter
Exercise of stock options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	28,339.00	shares	2 Qtrs
Exercise of stock options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	28,339.00	shares	2 Qtrs
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$26.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$26.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$80.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$80.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$11.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$11.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$43.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$43.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$11.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$11.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$18.00K	USD	1 Quarter
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$18.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$4.30M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$4.30M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$31.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$31.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$592.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$592.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$3.90M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$3.90M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-17.85M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-17.85M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-30.60M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-30.60M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.75M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.75M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-279.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-279.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-44.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-44.00K	USD	1 Quarter
Ending balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Ending balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Ending balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-74.98M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-74.98M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$373.21M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$373.21M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-57.76M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-57.76M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$436.10M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$436.10M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.